Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115154 | 0.90 | KDM4E (0.45) | KDM4EPKMHDAC1TP53KMT2A | |
| Dimethylamine SCHEMBL4126760 | 0.90 | ACHE (0.39) | KMT2ASMN1; SMN2HDAC4LMNAHTT | |
| SCHEMBL4131426 | 0.88 | KDM4E (0.43) | KDM4EPKMHDAC1TP53KMT2A | |
| Dimethylamine SCHEMBL4113447 | 0.87 | CETP (0.41) | SMN1; SMN2CYP2C19LMNAHTTGPR119 | |
| Dimethylamine SCHEMBL4114113 | 0.87 | TP53 (0.48) | TP53KMT2AMEN1LMNA | |
| SCHEMBL4134365 | 0.85 | KDM4E (0.40) | KDM4EPKMHDAC1TP53HDAC4 | |
| Dimethylamine SCHEMBL4129943 | 0.84 | KDM4E (0.41) | KDM4EPKMKMT2AGPR119 | |
| Dimethylamine SCHEMBL4114401 | 0.84 | ACHE (0.54) | KMT2AMEN1 | |
| Dimethylamine SCHEMBL4121979 | 0.83 | ACHE (0.53) | — | |
| Dimethylamine SCHEMBL4125334 | 0.83 | GPR119 (0.41) | KDM4EPKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | KDM4E 3136/4885PKM 2715/4885HDAC1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.